The human complement receptor type 2/factor H fusion protein TT30, an alternative pathway specific complement inhibitor, prevents hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria by membrane-targeting of factor H activity
| Autor: | Risitano, Antonio M., Pascariello, Caterina, Selleri, Carmine, Del Vecchio, Luigi, Sica, Michela, Fridkis-Hareli, Masha, Mazsaroff, Istvan, Horvath, Christopher J., Holers, V. Michael |
|---|---|
| Zdroj: | In Molecular Immunology 2010 47(13):2215-2215 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect